Skip to main content

Studies Further Validate Safety, Efficacy And An Improved Patient Experience In Use Of The C2 CryoBalloon® Ablation System For Primary Treatment Of Barrett's Esophagus

REDWOOD CITY, California, May 9, 2017 /PRNewswire/ — C2 Therapeutics marked Digestive Disease Week by releasing the results of clinical studies that help further validate the utility of the C2 CryoBalloon® Ablation System (CbAS) for ablation of Barrett’s esophagus.i
http://www.prnewswire.co.uk/news-releases/studies-further-validate-safety-efficacy-and-an-improved-patient-experience-in-use-of-the-c2-cryoballoon-ablation-system-for-primary-treatment-of-barretts-esophagus-621726663.html

Disclaimer: This information is for educational purposes only, It is not to diagnose or treat your disease. If you do use the information contained on this web site without the approval of a health professional, you are prescribing for yourself, which is your constitutional right, but the author(s) and webmaster assume no responsibility

© 2024 Esophageal Cancer Education Foundation- by domino